# Glaukos Corporation

Type: Company (GKOS)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/glaukos-corporation
Canonical HTML page: https://gethealthbrief.com/entity/glaukos-corporation

## Timeline

- **2026-02-21**: Q4 2025 Earnings — Both companies report record performance and optimistic 2026 outlooks.
- **2025-12-31**: Payer Milestone — Talkspace surpasses 140 million covered lives through payer partnerships.
- **2025-01-15**: Talkspace Profitability — Talkspace achieves its first full quarter of adjusted EBITDA profitability.
- **2024-03-01**: Commercial Launch — Initial rollout of iDose TR begins in the U.S. market with targeted accounts.
- **2023-12-14**: iDose TR FDA Approval — Glaukos receives landmark approval for its travoprost intracameral implant.

## Recent coverage (1 stories)

### Glaukos and Talkspace Cap 2025 with Record Growth in MedTech and Digital Health
2026-02-21 07:45:00 · Sentiment: Neutral · Impact: 5/10 · Sources: 5

Glaukos Corporation and Talkspace, Inc. reported strong Q4 2025 financial results, highlighting a successful transition toward high-margin, recurring revenue models. Glaukos saw significant gains from its iDose TR launch, while Talkspace solidified its position as a profitable, payer-led behavioral health leader.
Full story: https://gethealthbrief.com/story/glaukos-talkspace-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.